Published in Oral Oncol on March 09, 2010
Feasibility and Safety of Aerobic Exercise for Head and Neck Cancer Patients | NCT04679233
Swallowing dysfunction in cancer patients. Support Care Cancer (2011) 1.12
A systematic review of head and neck cancer quality of life assessment instruments. Oral Oncol (2012) 0.99
Psychometric properties of questionnaires on functional health status in oropharyngeal dysphagia: a systematic literature review. Biomed Res Int (2014) 0.98
An exploratory study of the influence of clinico-demographic variables on swallowing and swallowing-related quality of life in a cohort of oral and oropharyngeal cancer patients treated with primary surgery. Eur Arch Otorhinolaryngol (2011) 0.85
Measuring Outcomes for Dysphagia: Validity and Reliability of the European Portuguese Eating Assessment Tool (P-EAT-10). Dysphagia (2015) 0.83
Evaluation of swallowing by Sydney Swallow Questionnaire (SSQ) in oral and oropharyngeal cancer patients treated with primary surgery. Dysphagia (2012) 0.82
Validation in Swedish of Sydney swallow questionnaire. BMC Res Notes (2014) 0.77
Preliminary Evaluation of Functional Swallow After Total Laryngectomy Using High-Resolution Manometry. Ann Otol Rhinol Laryngol (2016) 0.75
Position paper of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery and the German Society of Phoniatrics and Pediatric Audiology - Current state of clinical and endoscopic diagnostics, evaluation, and therapy of swallowing disorders in children. GMS Curr Top Otorhinolaryngol Head Neck Surg (2015) 0.75
A Longitudinal Study of Symptoms of Oropharyngeal Dysphagia in an Elderly Community-Dwelling Population. Dysphagia (2016) 0.75
Translation, cross-cultural adaptation and validation of the Portuguese version of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis. Springerplus (2013) 0.75
Swallowing difficulties with medication intake assessed with a novel self-report questionnaire in patients with systemic sclerosis - a cross-sectional population study. Patient Prefer Adherence (2017) 0.75
Murray secretion scale and fiberoptic endoscopic evaluation of swallowing in predicting aspiration in dysphagic patients. Eur Arch Otorhinolaryngol (2017) 0.75
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol (2011) 7.46
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med (2012) 4.59
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res (2006) 2.35
A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res (2008) 2.18
The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther (2009) 2.14
Alternative splicing of ryanodine receptors modulates cardiomyocyte Ca2+ signaling and susceptibility to apoptosis. Circ Res (2007) 1.83
Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol (2011) 1.82
Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther (2008) 1.78
Stereotactic body radiotherapy for oligometastases. Lancet Oncol (2013) 1.76
Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol (2008) 1.70
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res (2012) 1.67
Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res (2010) 1.63
Assessment and management of dysphagia in patients with head and neck cancer who receive radiotherapy in the United Kingdom - a web-based survey. Oral Oncol (2011) 1.58
Making sense of post-treatment surveillance in head and neck cancer: when and what of follow-up. Cancer Treat Rev (2009) 1.58
Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res (2008) 1.56
Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer: a prospective observational study. Int J Radiat Oncol Biol Phys (2010) 1.55
Reconstruction of pharyngolaryngectomy defects using the jejunal free flap: a 10-year experience from a single reconstructive center. Plast Reconstr Surg (2010) 1.54
Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels. Int J Radiat Oncol Biol Phys (2006) 1.53
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res (2010) 1.53
Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res (2009) 1.50
99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer. J Nucl Med (2002) 1.44
Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res (2008) 1.44
Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res (2002) 1.42
Should the treatment paradigms for oral and oropharyngeal cancers be changed now: the role of human papilloma virus? ANZ J Surg (2011) 1.40
Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res (2010) 1.35
Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev (2005) 1.31
Targeting HOX and PBX transcription factors in ovarian cancer. BMC Cancer (2010) 1.29
Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol (2009) 1.25
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer (2011) 1.17
Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Res (2002) 1.13
Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin Cancer Res (2011) 1.12
Overcoming obstacles to research in residency. JAMA (2013) 1.10
The impact of introducing intensity modulated radiotherapy into routine clinical practice. Radiother Oncol (2005) 1.10
Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. BMC Cancer (2012) 1.09
Head and neck cancer in the elderly: an overview on the treatment modalities. Cancer Treat Rev (2008) 1.08
Key molecular mechanisms in lung cancer invasion and metastasis: a comprehensive review. Crit Rev Oncol Hematol (2013) 1.05
Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. Mod Pathol (2012) 1.03
Non-Hodgkin's lymphoma of the sino-nasal tract in children. J Cancer Res Ther (2010) 1.03
The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma. Oral Oncol (2002) 1.03
Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol (2009) 1.02
Current status and future prospects in prosthetic voice rehabilitation following laryngectomy. J Cancer Res Ther (2008) 1.00
The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. PLoS One (2012) 0.98
Intensity Modulated Radiotherapy (IMRT) in locally advanced thyroid cancer: acute toxicity results of a phase I study. Radiother Oncol (2007) 0.98
Targeting the HOX/PBX dimer in breast cancer. Breast Cancer Res Treat (2012) 0.97
Signaling pathways required for matrix metalloproteinase-9 induction by betacellulin in head-and-neck squamous carcinoma cells. Int J Cancer (2004) 0.97
Dosimetric explanations of fatigue in head and neck radiotherapy: an analysis from the PARSPORT Phase III trial. Radiother Oncol (2012) 0.97
Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck. J Pathol (2009) 0.97
Comprehensive review of small bowel metastasis from head and neck squamous cell carcinoma. Oral Oncol (2010) 0.97
Strategies to reduce long-term postchemoradiation dysphagia in patients with head and neck cancer: an evidence-based review. Head Neck (2013) 0.96
Implications of understanding cancer stem cell (CSC) biology in head and neck squamous cell cancer. Oral Oncol (2011) 0.96
Assessment of a customised immobilisation system for head and neck IMRT using electronic portal imaging. Radiother Oncol (2005) 0.96
Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells. Int J Cancer (2012) 0.95
Contemporary clinical commentary: esthesioneuroblastoma: an update on management of the neck. Laryngoscope (2003) 0.95
How should we manage oral leukoplakia? Br J Oral Maxillofac Surg (2012) 0.95
The value of magnetic resonance imaging in target volume delineation of base of tongue tumours--a study using flexible surface coils. Radiother Oncol (2010) 0.94
Swallowing outcomes following Intensity Modulated Radiation Therapy (IMRT) for head & neck cancer - a systematic review. Oral Oncol (2010) 0.94
A modified inflammatory bowel disease questionnaire and the Vaizey Incontinence questionnaire are more sensitive measures of acute gastrointestinal toxicity during pelvic radiotherapy than RTOG grading. Int J Radiat Oncol Biol Phys (2006) 0.94
Dose-response analysis of parotid gland function: what is the best measure of xerostomia? Radiother Oncol (2013) 0.93
Novel targeted radiosensitisers in cancer treatment. Curr Drug Discov Technol (2009) 0.93
Correlation between dose to the pharyngeal constrictors and patient quality of life and late dysphagia following chemo-IMRT for head and neck cancer. Radiother Oncol (2009) 0.93
Targeted radiosensitization by the Chk1 inhibitor SAR-020106. Int J Radiat Oncol Biol Phys (2012) 0.93
Quality of life and outcomes research in head and neck cancer: a review of the state of the discipline and likely future directions. Cancer Treat Rev (2009) 0.92
Tracheo-oesophageal party wall thickness in laryngectomised patients in India: implications for surgical voice restoration. J Surg Oncol (2010) 0.92
Intensity-modulated radiotherapy improves target coverage, spinal cord sparing and allows dose escalation in patients with locally advanced cancer of the larynx. Radiother Oncol (2004) 0.92